Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population …

T Benfield, J Bodilsen, C Brieghel… - Clinical Infectious …, 2021 - academic.oup.com
Background There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …
被引用次数：57 相关文章
[HTML] nih.gov

[HTML][HTML] Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide …

T Benfield, J Bodilsen, C Brieghel, ZB Harboe… - … Infectious Diseases: An … - ncbi.nlm.nih.gov
Background There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …

Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population …

T Benfield, J Bodilsen, C Brieghel… - Clinical Infectious …, 2021 - portal.findresearcher.sdu.dk
BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus
disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a …

Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population …

T Benfield, J Bodilsen, C Brieghel… - … Diseases: an Official …, 2021 - europepmc.org
Background There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …

Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population …

T Benfield, J Bodilsen, C Brieghel, ZB Harboe… - Clinical Infectious …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
There are limited data on outcomes of moderate to severe coronavirus disease 2019 …

Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population …

T Benfield, J Bodilsen, C Brieghel… - Clinical Infectious …, 2021 - search.ebscohost.com
Background There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …

Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population …

T Benfield, J Bodilsen, C Brieghel… - … diseases: an official …, 2021 - research.regionh.dk
BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus
disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a …

Improved survival among hospitalized patients with Coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population …

T Benfield, J Bodilsen, C Brieghel, ZB Harboe… - 2021 - cabidigitallibrary.org
Background: There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …

Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population …

T Benfield, ZFB Harboe, S Johnsen, BL Madsen… - ikm.ku.dk
BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus
disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a …
[PDF] researchgate.net

[PDF][PDF] Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide …

T Benfield, J Bodilsen, C Brieghel, ZB Harboe… - 2021 - researchgate.net
Background. There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …